Abstract

BackgroundGATA binding protein 3 (GATA3) was recently proposed to function as a tumor suppressor gene in some types of human cancer. This study aims to investigate GATA3 expression and its prognostic significance in primary gastric adenocarcinoma.Methodology/Principal FindingsUsing real-time quantitative PCR (RT-qPCR) and immunohistochemical staining methods, GATA3 expression was analyzed in tissue samples from a consecutive series of 402 gastric adenocarcinoma patients who underwent resections between 2003 and 2006. The relationship between GATA3 expression, clinicopathological factors, and patient survival was investigated. The expression status of GATA3 was shown to be clearly reduced in the tumor tissue samples compared with that in the matched adjacent non-tumor tissue samples by RT-qPCR (P = 0.0014). Immunohistochemistry analysis indicated that GATA3 expression was significantly decreased in 225 of the 402 (56%) gastric adenocarcinoma cases. Reduced GATA3 expression was also observed in patients with large tumors (P = 0.017), signet ring cell carcinoma or mucinous carcinoma (P = 0.005) and tumors with lymphatic or venous invasion (P = 0.040). Additionally, reduced expression of GATA3 was more commonly observed in tumors that were staged as T4a/b (P<0.001), N3 (P<0.001), or M1 (P<0.001). Kaplan-Meier survival curves revealed that reduced expression of GATA3 was associated with poor prognosis in gastric adenocarcinoma patients (P<0.001). Multivariate Cox analysis identified GATA3 expression as an independent prognostic factor for overall survival (HR = 5.375, 95% CI = 3.647–7.921, P<0.001). To investigate the predictive ability of the models with and without containing GATA3 gene expression, Harrell's c-index was calculated as a measure of predictive accuracy of survival outcome. The c-index values revealed that model containing GATA3 expression (c-index = 0.897) had superior discrimination ability to the model without containg it (c-index = 0.811).Conclusions/SignificanceOur data suggest that GATA3 plays an important role in tumor progression and that reduced GATA3 expression independently predicts an unfavorable prognosis in primary gastric adenocarcinoma patients.

Highlights

  • Gastric cancer is the fourth most common type of malignant tumor worldwide and the second most common cause of cancerrelated deaths each year [1]

  • Analysis of GATA binding protein 3 (GATA3) mRNA Expression by real-time quantitative PCR (RT-qPCR) The levels of GATA3 mRNA in 38 pairs of resected specimens from eligible gastric cancer patients were estimated by Reverse transcription (RT)-qPCR

  • The present study suggests that GATA3 expression is correlated with the clinicopathological parameters of gastric cancer patients and that its low expression independently predicts worse overall survival in patients with gastric adenocarcinoma

Read more

Summary

Introduction

Gastric cancer is the fourth most common type of malignant tumor worldwide and the second most common cause of cancerrelated deaths each year [1]. Nearly 60% of patients succumb to gastric cancer, even after curative resection or adjuvant therapy [2]. The confirmation of several new oncogenes and tumor suppressor genes that are associated with gastric cancer may be useful for early diagnosis and the development of molecularly targeted therapies [3,4]. To improve the prognosis of gastric adenocarcinoma, a better understanding of the molecular mechanisms of cancer progression and the development of new therapeutic tools based on these mechanisms are required [3,5,6,7]. This study aims to investigate GATA3 expression and its prognostic significance in primary gastric adenocarcinoma

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call